Head and Neck Cancers Coverage from Every Angle

Adding Nimotuzumab to Chemoradiotherapy in Locally Advanced Head and Neck Cancer

By: Sarah Campen, PharmD
Posted: Wednesday, August 28, 2019

The addition of nimotuzumab to a combination of radical radiotherapy with concurrent weekly cisplatin appears to prolong progression-free survival in patients with locally advanced head and neck squamous cell carcinoma compared with radiotherapy plus weekly cisplatin alone. According to a phase III trial published in Cancer, adding the humanized monoclonal antibody directed against EGFR also significantly improved disease-free survival and the duration of locoregional tumor control.

“This combination provides a novel alternative therapeutic option to a 3-weekly schedule of 100 mg/m2 cisplatin in patients with locally advanced head and neck cancer who are treated with radical-intent [radiotherapy with concurrent weekly cisplatin],” stated Vijay Maruti Patil, MD, of Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, and colleagues.

In this open-label study, 536 patients were randomly assigned to receive either radical radiotherapy (66–70 Gy) with concurrent weekly cisplatin (30 mg/m2) or the same regimen plus weekly nimotuzumab (200 mg). Patients were followed for a median of 39.13 months.

The addition of nimotuzumab significantly improved 2-year progression-free survival (61.8% vs. 50.1%; P = .004). The nimotuzumab arm also had a 33% reduction (P = .006) in the risk of locoregional failure and an improvement in 2-year disease-free survival (60.2% vs. 48.5%). Although there was a trend toward improving overall survival (63.8% vs.57.7%), the difference was not statistically significant. As for safety, grade 3 to 5 adverse events were similar between the two arms, although a higher incidence of mucositis was observed with nimotuzumab.

Disclosure: The study authors’ disclosure information may be found at onlinelibrary.wiley.com.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.